Sangamo Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Sangamo Therapeutics, Inc. (SGMO)
Portfolio Pulse from
Levi & Korsinsky is investigating Sangamo Therapeutics for potential securities fraud after Pfizer returned the rights to a co-developed hemophilia A gene therapy candidate, raising concerns about Sangamo's disclosures.
January 17, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sangamo Therapeutics is under investigation for potential securities fraud after Pfizer returned the rights to a co-developed hemophilia A gene therapy candidate. This raises concerns about Sangamo's disclosures and could impact investor confidence.
The investigation by Levi & Korsinsky into potential securities fraud is significant as it questions the transparency of Sangamo's disclosures. The return of rights by Pfizer, a major partner, could indicate issues with the therapy's viability, impacting investor sentiment negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100